Phase 2 randomized, dose-ranging trial of CTP-543, a selective Janus Kinase inhibitor, in moderate-to-severe alopecia areataBrett King, James V. Cassella, Emma Guttman‐Yassky et al.|Journal of the American Academy of Dermatology|2022Cited by 80